Comparison · NCT00566501-deaths
Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) vs Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) vs Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205): deaths from any cause. Trial comparisons, record NCT00566501-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00566501-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0246 | 0.0147 | 0.0408 | wilson | |
| Risk in group 2 | 0.0151 | 0.00645 | 0.0348 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0095 | -0.0125 | 0.0279 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.63 | 0.593 | 4.49 | log | |
| Odds ratio, group 1 over group 2 | 1.65 | 0.588 | 4.61 | log | |
| Number needed to harm, for one more death from any cause on Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) than on Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | 105 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205) | Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205). | 14 | 570 | EG000 |
| Group 2 | Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205) | Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg IR in the preceding double-blind study E2020-G000-326 (NCT00478205). | 5 | 332 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From the first dose of study drug up to 2 years 3 months
Source ClinicalTrials.gov
Trial
- Title
- Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
- NCT number
- NCT00566501
- Phases
- PHASE3
- Conditions
- Alzheimer's Disease
- Interventions
- Donepezil
- Lead sponsor
- Eisai Inc.
- Results first posted
- 2012-06-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00566501?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00566501-deaths